From: Gastrointestinal peptides in children before and after hematopoietic stem cell transplantation
Number of patients | 27 |
Sex | boys-20, girls-7 |
Age (years) | 1.5–19 (mean 9, median 9.6) |
Neoplastic diseases, n (n %) | 18 (67%) |
Chemotherapy before HSCT, n (n %) | 17 (63%) |
Local radiotherapy | 5 (CNS-4,Testes-1) |
Time since diagnosis (years) | |
Neoplastic diseases | Median-1, mean-2; range 0.1–7 |
Non-neoplastic diseases | Median-1.5, mean-3.8, range 0.1–13 |
Conditioning regimen based on busulfan or treosulfan, n (n %) | 16(60%) |
Total body irradiation – 12Gy/6fractions, n (n %) | 7 (26%) |
GvHD prophylaxis, n (n %) | |
CSA | 4 (15%) |
MTX + CSA | 23 (85%) |
Mucositis, n (%) | 22 (82%) |
Grade, n | I-7, II-8, III-6, IV-1 |
Intravenous alimentation due to mucositis (%) | 48 |
aGvHD, n (n %) | 11 (41) |
Localisation, % | Gut-9, Skin-91, Liver-27 |
Grade, n | IA-1, IB-4, IIB-1, IIC-3, IIIC-2 |
Systemic glucocorticoid treatment, n (%) | 19 (70) |
Systemic glucocorticoid treatment (days) | Median-3.5, mean-3.6; range 0.1–11 |
Time from discontinuation of systemic glucocorticoids to the second assessment (months) | Median-3.6, mean-4.5; range 0.5–14 |
Time from discontinuation of immunosuppressive treatment to the second assessment (months) | Median 1.6; range 0–9 |
Time from HSCT to the second assessment (months) | Median 6.3 (5.9–19.1) |